tbuckley/cabot-search huggingface dataset:
Prognostic Significance of Vascular Endothelial Growth Factor Protein Levels in Oral and Oropharyngeal Squamous Cell Carcinoma
Authors: Benjamin D. Smith, Grace L. Smith, Darryl Carter, Clarence T. Sasaki, Bruce G. Haffty
Journal: Journal of Clinical Oncology (2000)

PURPOSE: Vascular Endothelial Growth Factor (VEGF) promotes angiogenesis in many different tumor types. VEGF levels may affect tumor growth, metastatic potential, and response to radiotherapy. This study assesses the prognostic value of VEGF protein levels in a cohort of patients with oral and oropharyngeal squamous cell carcinomas. The relationships between clinical outcome and the covariables of tumor-node-metastasis stage, disease stage (I to IV), grade, margin status, race, sex, and age were also determined. PATIENTS AND METHODS: Chart review identified 77 patients with oral or oropharyngeal squamous cell carcinoma treated with gross total surgical resection and postoperative radiation between 1981 and 1992. Sufficient follow-up data and tumor tissue were available in 56 patients (73%). VEGF protein levels were determined using immunohistochemistry. The association between VEGF status, covariables, and outcome was assessed in a bivariate and multivariate model using two-sided statistical tests. RESULTS: Twenty-three tumors (41%) were positive for VEGF expression. VEGF-positive tumors were more likely to recur locally (relative risk [RR] = 3.08; 95% confidence interval [CI], 1.03 to 9.24) and distantly (RR = 4.62; 95% CI, 1.41 to 15.10). In bivariate analysis, VEGF positivity was the most significant predictor of poor disease-free survival (RR = 2.66; 95% CI, 1.27 to 5.56) and overall survival (RR = 3.21; 95% CI, 1.63 to 6.32). In multivariate analysis, VEGF positivity was the most significant predictor of poor disease-free survival (RR = 2.75; 95% CI, 1.30 to 5.79) and overall survival (RR = 3.53; 95% CI, 1.75 to 7.13). CONCLUSION: In this cohort, VEGF positivity was the most significant predictor of poor prognosis. VEGF status may prove to be an important prognostic factor in head and neck cancer.
Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy
Authors: Ismail Jatoi, Hanna Bandos, Jong-Hyeon Jeong, William F. Anderson, Edward H. Romond, Eleftherios P. Mamounas, Norman Wolmark
Journal: JNCI Journal of the National Cancer Institute (2015)

Background:The benefits of breast cancer adjuvant systemic treatments are generally assumed to be proportional (or constant) over time, but limited data suggest that some treatment effects may vary with time. We therefore systematically assessed the proportional hazards assumption across all 19 breast cancer adjuvant systemic therapy trials in the National Surgical Adjuvant Breast and Bowel Project (NSABP) database.
Even small brain lesions raise risk of stroke and death, study finds
Authors: Jacqui Wise
Journal: BMJ (2015)

Even very small brain lesions detected by magnetic resonance imaging (MRI) should not be dismissed, researchers have said.1

Subclinical brain infarctions are usually defined as larger than 3 mm in patients with no history of clinical stroke, and those that are smaller than this are typically ignored.

But a new study published in Annals of Internal Medicine found that, in …
Hemodynamic effects of Cheyne-Stokes respiration in heart failure?
Authors: Olaf Oldenburg, Henrik Fox, Jens Spießhöfer, Thomas Bitter, Dieter Horstkotte
Journal: European Respiratory Journal (2014)

Cheyne-Stokes respiration (CSR) in heart failure (HF) patients is characterized by hyperventilation (HV) with low arterial partial pressure of CO 2  (pCO 2 ). It is still questioned whether this HL characterizes a compensatory response to HF or represents an independent comorbidity. Aim of the present study was to investigate the hemodynamic effects of HL.  Hemodynamic effects of voluntary HV were investigated in 15 healthy volunteers (HVOL; 13 male, 25±4 years, BNP  55%) and 19 HF patients (14male, 67±12years, NYHA class 2.6±0.6, BNP 802±839pg/ml, LV-EF 33.5 ±9.0%). Non-invasive hemodynamic monitoring was used in HVOL whereas invasive measurements were used in HF patients. Transcutaneous (tc) pCO 2  was used in HVOL and aortal blood gas analysis was used in HF patients to verify and quantify HV.  During HV PtcCO 2  in HVOL dropped from 38.74±2.5 to 28.6±3.3 mmHg (p 2  in HF patients from 33.0 ± 3.6 to 22.3 ± 3.3mmHg (p  HV leads to an increase in cardiac output in healthy volunteers as well as in heart failure patients. This increase is mainly due to an increase in heart rate. Cheyne-Stokes respiration with associated hyperventilation might be a compensatory mechanism in patients with a failing heart, but because this is due to an increase in heart rate, it might be deleterious in the long run.
Allergic bronchopulmonary aspergillosis with middle lobe syndrome and allergic Aspergillus sinusitis
Authors: A Shah, R Bhagat, N Panchal, O P Jaggi, Z U Khan
Journal: European Respiratory Journal (1993)

A 55 year old male, who had a 12 yr history of rhinorrhoea and nasal blockage, presented with a middle lobe syndrome. Evaluation of the patient led to the diagnosis of concomitant allergic bronchopulmonary aspergillosis with allergic Aspergillus sinusitis, a rarely reported association.
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
Authors: A H Sarris, A Younes, P McLaughlin, D Moore, F Hagemeister, F Swan, M A Rodriguez, J Romaguera, L North, P Mansfield, D Callendar, O Mesina, F Cabanillas
Journal: Journal of Clinical Oncology (1996)

PURPOSE Cyclosporin A has been shown to reverse paclitaxel resistance in vitro by inhibiting P-gp function. Therefore, we determined whether addition of cyclosporine to paclitaxel reversed clinical paclitaxel resistance in patients with non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Patients with relapsed NHL were eligible if they had no intervening treatment after failure to respond to paclitaxel (200 mg/m2 over 3 hours), and if they had adequate marrow, renal, and hepatic function, no serious cardiac disease, no CNS involvement, and no antibodies to human immunodeficiency virus-1. A cyclosporin A bolus dose (5 mg/kg over 3 hours) was followed by intravenous infusion (15 mg/kg) over 24 hours. Six hours after the beginning of cyclosporin A, the immediately preceding paclitaxel dose was administered over 3 hours. All patients were premedicated with dexamethasone, diphenhydramine, and cimetidine. Response was assessed after two cycles, and those patients who achieved at least a partial response received a maximum of six courses. RESULTS All 26 patients entered were assessable for toxicity and 25 were assessable for response. One patient whose disease had progressed during paclitaxel treatment had a partial remission after the addition of cyclosporin A (response rate, 4%; 95% confidence interval, 1% to 20%). Disease progressed in 17 patients (71%) and did not respond in seven (25%). Serum cyclosporin A A levels measured at the time of initiation of paclitaxel infusion were greater than 2,000 ng/mL during 81% of cycles. Treatment toxicity included peripheral neuropathy in 57%, myalgia or arthralgia in 30%, neutropenia in 53%, neutropenic fever in 8%, and thrombocytopenia in 42% of patients. One patient with preexisting asthma had an acute bronchospasm during the first cycle and was removed from the study. There were no renal or hepatic toxicity and no infectious or hemorrhagic deaths. CONCLUSION Cyclosporin A administered on this schedule did not reverse established clinical resistance to paclitaxel, which suggests that P-gp-mediated drug efflux is unlikely to be the only cause of paclitaxel resistance in this patient population.
Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival
Authors: Eric J. Small, Alex McMillan, Mark Meyer, Liang Chen, William J. Slichenmyer, Peter F. Lenehan, Mario Eisenberger
Journal: Journal of Clinical Oncology (2001)

PURPOSE: Validated end points are lacking for clinical trials in hormone-refractory prostate cancer (HRPC). Controversy remains regarding the utility of a posttreatment decline of prostate-specific antigen (PSA). The purpose of this study was to determine whether posttreatment declines in PSA were associated with clinical measures of improvement in a randomized phase III trial of suramin plus hydrocortisone versus placebo plus hydrocortisone. PATIENTS AND METHODS: A total of 460 HRPC patients were randomized to receive suramin plus hydrocortisone (n = 229) or placebo plus hydrocortisone (n = 231). All patients had symptomatic, metastatic HRPC requiring opioid analgesics. Clinical end points evaluated included overall survival, objective progression-free survival (OPFS), and time to pain progression (TTPP). An evaluation of overall survival, OPFS, and TTPP as a function of a PSA decline of ≥ 50%, lasting at least 28 days, was undertaken by using a landmark analysis at 6, 9, and 12 weeks. A multivariate analysis of the impact of PSA decline was performed on these clinical end points. RESULTS: A decline in PSA of ≥ 50% lasting ≥ 28 days was significantly associated with a prolonged median overall survival, OPFS, and TTPP, both in the entire group and the suramin plus hydrocortisone group at all three landmarks in both univariate and multivariate analysis. CONCLUSION: In this prospective, randomized trial of suramin plus hydrocortisone versus placebo plus hydrocortisone, a posttherapy decline in PSA of ≥ 50%, lasting 28 days, was associated with prolonged median overall survival, improved median progression-free survival, and median TTPP. This analysis suggests that a posttreatment decline in PSA may be a reasonable intermediate end point in HRPC trials and calls into question the clinical utility of preclinical assays evaluating the in vitro effect of given agents on PSA secretion.
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.
Authors: P W Johnson, A Z Rohatiner, J S Whelan, C G Price, S Love, J Lim, J Matthews, A J Norton, J A Amess, T A Lister
Journal: Journal of Clinical Oncology (1995)

To examine outcome of treatment for patients with recurrent follicular lymphoma.Two hundred twelve newly diagnosed follicular lymphoma patients were studied. One hundred seventy-nine were initially treated successfully. Recurrent or progressive lymphoma developed in 116. Treatment was given according to disease stage and current protocols, mostly with single alkylating agents. A policy of repeated lymph node and bone marrow biopsy was pursued.The overall median survival duration was 9 years, with a median follow-up duration of 12 years. Following recurrence, the median survival duration was 4 1/2 years. Only eight of 116 patients with recurrent disease died of causes unrelated to lymphoma. The overall response rate to first re-treatment was 78% and showed slight decline with successive recurrences, reaching 48% after the fourth treatment. The median duration of second remission was 13 months, (v 31 months for first remission), with the only significant predictive factor being quality of remission. Multivariate analysis showed only age at recurrence and number of prior treatments to correlate with survival after first recurrence. Survival after second remission was only correlated with age and quality of response: Kaplan-Meier estimates gave 53% of patients reaching second complete remission alive 10 years later, compared with 28% in partial remission.Age and previous and continuing responsiveness of follicular lymphoma to therapy are the principal determinants of survival following recurrence. Improvement in survival with new treatments will be demonstrated most readily in older patients, while more intensive approaches should be tested in younger patients in whom remission is achieved with difficulty.
Immunosuppression by &lt;italic&gt;Bis&lt;/italic&gt;dioxopiperazines: Effects on Antibody-Forming Cells and Serum Titers
Authors: D. F. Tucker, Mavis D. Finch
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Immunosuppression by Bisdioxopiperazines: Effects on Antibody-Forming Cells and Serum Titers Get access D. F. Tucker, D. F. Tucker Cancer Chemotherapy Department, Imperial Cancer Research Fund, Lincoln's Inn Fields, London, W.C.2., England Search for other works by this author on: Oxford Academic PubMed Google Scholar Mavis D. Finch Mavis D. Finch Cancer Chemotherapy Department, Imperial Cancer Research Fund, Lincoln's Inn Fields, London, W.C.2., England Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 5, May 1972, Pages 1347–1354, https://doi.org/10.1093/jnci/48.5.1347 Published: 01 May 1972 Article history Received: 27 September 1971 Accepted: 19 January 1972 Published: 01 May 1972
Absolute neutrophil count (ANC) pattern with accelerated dose-intensified epirubicin chemotherapy and pegfilgrastim support
Authors: E. Segota, S. Misbah, J. Crowe, R. Tubbs, G. Casey, P. Elson, B. Wacker, G. T. Budd
Journal: Journal of Clinical Oncology (2004)

8229 Background: Several randomized studies evaluating pegfilgrastim and filgrastim have shown no difference in ANC patterns in cycle 2 compared to cycle 1 of chemotherapy. We have observed an interesting ANC pattern in a phase II clinical study evaluating the safety and efficacy of accelerated dose- intensified neoadjuvant epirubicin with pegfilgrastim support in patients with breast cancer. Methods: Biopsy proven stage II/III breast cancer patients with primary tumors >2 cm and adequate hematologic, hepatic, renal, and cardiac function are eligible. Single agent epirubicin is given at 120 mg/m2 every 14 days for four cycles with pegfilgrastim support (6 mg subcutaneously once per cycle 24 hours following each treatment). Definitive surgery is performed 3–4 weeks after completion of chemotherapy. Postoperative therapy is given at the discretion of the investigator. Planned accrual is 30 patients. Results: To date 6 patients have been treated. All 6 have completed chemotherapy, and have undergone surgery. Two patients achieved a clinical complete response, 3 patients had a partial response, and 1 patient has stable disease. Grade 4 neutropenia (ANC<0.5 k/uL) was noted in all 6 patients following cycle 1 of chemotherapy. During cycles 2–4, no grade 4, and only 1 case of grade 3 neutropenia (ANC<0.5 k/uL) was observed in a total of 18 cycles of therapy given (Table). Conclusions: Accelerated, dose intensified epirubicin with pegfilgrastim is safe and appears efficacious as neoadjuvant therapy. The finding of grade 4 neutropenia in all patients after the first dose of epirubicin, but decreased myelosuppression with subsequent chemotherapy cycles suggests a “priming” effect of pegfilgrastim and warrants further study. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer
Abstract 16150: A Novel Blood-based Assay for Accurate Diagnosis of Coronary Artery Disease and Acute Coronary Syndromes Based on a Leukocyte Capture CD Antibody Microarray
Authors: Cris G dos Remedios, Alana Mohamed, Joshua W Ho, Andy Yong, Wayne Dyer, David Sullivan, Leonard Kritharides, Ben Freedman
Journal: Circulation (2010)

Introduction: No blood test is currently available to diagnose the presence of coronary artery disease (CAD), or non-MI acute coronary syndromes (ACS). We developed an antibody microarray blood test to positively identify patients with CAD and ACS with high reliability, based on 100–150 different antibodies directed against cell-surface leukocyte CD antigens. Antibody dots separated by 1 mm are robotically arrayed in duplicate pattern on a nitrocellulose-coated glass slide. Methods: We isolated peripheral blood mononuclear cells (PBMCs) from 5–10ml of venous blood and applied 4 × 106 cells to the moistened array. Anti-CD antibody dots (450 μ diameter) capture PBMCs displaying corresponding antigens, where the number of immobilized PBMCs is proportional to the number in the applied sample. Differential patterns of dot intensities arise from the light scattered from each dot and represent captured T cells, B cells, monocytes and other mononuclear cells. These patterns (see Figure) were used to differentiate...
Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation
Authors: Barbara Fowble, Alexandra Hanlon, Gary Freedman, Art Patchefsky, Howard Kessler, Nicos Nicolaou, John Hoffman, Elin Sigurdson, Marcia Boraas, Lori Goldstein
Journal: Journal of Clinical Oncology (1999)

PURPOSE: To compare the pretreatment characteristics and outcome of postmenopausal women with stage I-II breast cancer treated with conservative surgery and radiation who had a history of hormone replacement therapy (HRT) with those who had never received HRT. MATERIALS AND METHODS: From 1979 to 1993, 485 postmenopausal women underwent excisional biopsy, axillary dissection, and radiation for stage I-II breast cancer. The median follow-up was 5.9 years. One hundred forty-one patients reported a history of HRT. The median length of use was 5 years. Three hundred forty-four patients reported no history of HRT. RESULTS: Statistically significant differences between the two groups were observed for median age (HRT 60 years v no HRT 64 years; P = .0009), median weight (HRT 142 lbs v no HRT 152 lbs; P = .004), clinical tumor size ≤ 2 cm (HRT 77% v no HRT 66%; P = .02), and the use of re-excision (HRT 62% v no HRT 49%; P = .01). The method of detection by mammogram only (HRT 52% v no HRT 42%; P = .06) was of borderline statistical significance. The HRT patients had a statistically significant increased cumulative incidence of ipsilateral breast tumor recurrence (8% v 2%; P = .02), a statistically significant decreased cumulative incidence of distant metastases (HRT 6% v no HRT 17%; P = .01), and a borderline statistically significant improvement in cause-specific survival at 10 years (HRT 92% v no HRT 86%; P = .07). Postmenopausal women with a history of HRT did not have an increased risk of contralateral breast cancer or second non–breast cancer malignancy. CONCLUSION: This study failed to identify an adverse effect of HRT on breast cancer mortality in patients with stage I-II disease treated with conservative surgery and radiation.
Pathological Lesions of the External Auditory Meatus: A Review
Authors: I Friedmann
Journal: Journal of the Royal Society of Medicine (1990)

A closer study of the pathology of the external auditory meatus shows that there are various nonneoplastic and neoplastic diseases of local origin which are of great clinico-pathological importance. These include Kimura's disease and angiolymphoid hyperplasia with eosinophilia; progressive necrotizing (or malignant) external otitis. Osteoma and ceruminoma are typical neoplasms of the external auditory meatus which is also the site of polypoid granulomatous or neoplastic structures arising from the middle ear cleft. These so-called ‘aural polyps’ often dismissed as of little or no diagnostic importance, may contain significant clues to a serious underlying infection or to a malignant neoplasm. Profuse bleeding may ensue on removal of such polyps. The histopathological features and their significance are described and discussed.
Vascularization of Melanoma by Mobilization and Remodeling of Preexisting Latent Vessels to Patency
Authors: Weixin Lu, Alan Jay Schroit
Journal: Cancer Research (2005)

Abstract Tumors must manipulate the host vasculature to provide a blood supply adequate for their proliferation. Although tumors may arise as avascular masses, there is increasing evidence that some tumors begin to proliferate by first co-opting preexisting host blood vessels. By fluorescent vascular imaging, we provide evidence that the vasculature in orthotopically implanted melanoma arises from a preexisting red cell–deficient vascular network that remodels to patency to accommodate the requirements of the expanding tumor mass. Topical application of vascular endothelial growth factor to vascular beds generated immediate and robust vascular transitions that were morphologically similar to tumor-induced transitions. Nφ-nitro-l-arginine, a nitric oxide inhibitor, significantly inhibited the growth of a syngeneic K1735M2 melanoma by reducing blood supply to the tumor by a mechanism independent of endothelial cell proliferation. These findings suggest that tumor-induced remodeling of red cell–deficient vessels to patency contributes to tumor vascularization and growth.
Cardiac Magnetic Resonance Imaging Findings and the Risk of Cardiovascular Events in Patients With Recent Myocardial Infarction or Suspected or Known Coronary Artery Disease
Authors: Hamza El Aidi, Arthur Adams, Karel G.M. Moons, Hester M. Den Ruijter, Willem P.Th.M. Mali, Pieter A. Doevendans, Eike Nagel, Simon Schalla, Michiel L. Bots, Tim Leiner
Journal: Journal of the American College of Cardiology (2014)
Abstract 703: Usefulness of Dual Doppler System in Estimating Left Ventricular Filling Pressure in Patients with Atrial Fibrillation -Temporal Analysis of Simultaneous Measurement of Transmitral Inflow and Mitral Annular Velocity-
Authors: Yasuaki Wada, Kazuya Murata, Takeo Tanaka, Yoshio Nose, Chikage Kihara, Yasuhiro Fukagawa, Hiroko Yoshino, Takehisa Susa, Masunori Matsuzaki
Journal: Circulation (2008)

Background: A ratio of early transmitral flow velocity (E) to early diastolic mitral annular velocity (E′) and a time interval between onsets of E and E′ (T E′-E ) has been proposed as a novel index to assess left ventricular (LV) filling pressure (FP). However, in patients with atrial fibrillation (AF), it is often difficult to obtain steady Doppler-derived values because of fluctuating R-R intervals. Recently, simultaneous recording of E and E′, and calculation of E/E′ and T E′-E n each cardiac cycle has been feasible with dual Doppler system (Hitachi EUB7500). Methods: Forty patients with AF were analyzed to evaluate the feasibility for estimating LVFP by simultaneous recording of E and E′. We measured E/E′ and T E′-E corrected by R-R interval (cT E′-E ) using a dual Doppler system, and LV pre-atrial pressure (pre-A) in 5 consecutive cardiac cycles. Results: E/E′ and cT E′-E had significant correlations with pre-A (E/E′: r=0.58, p&lt;0.001; cT E′-E : r=0.78, p&lt;0.001). The receiver-operating characteristic (ROC) analysis revealed that cut-off value of cT E′-E &gt;34ms 0.5 had higher specificity and sensitivity to predicted pre-A&gt;12mmHg than the value of E/E′ &gt;10.1 (cT E′-E : sensitivity 94%, specificity 87%, E/E′: sensitivity 67%, specificity 43%). Conclusions: Even in patients with AF, the temporal analysis of E and E′ by the dual Doppler system was available for estimating elevated LVFP and provided an incremental value in addition to velocity analysis of pulsed and tissue Doppler indices.